Manejo de sirolimus en la práctica clínica

Nefrologia

Volumn 26, Issue SUPPL.2, 2006, Pages 64-93

  Oppenheimer, Federico ^a   Alonso, A ^b   Arias, M ^c   Campistol, J M ^a   Gonzalez Molina M ^d   Gonzalez Posada J M ^e   Grinyo, J M ^f   Morales, J M ^g   Sanchez Fructuoso A ^h   Sanchez Plumed J ⁱ   Ruiz, J C ^c  

^a Hospital Clinic   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d Hospital Carlos Haya   (Spain)

^e Hospital Universitario Tenerife   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h Hospital Clínico   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ANIMAL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CONGENITAL MALFORMATION; CONSENSUS DEVELOPMENT; DRUG COMBINATION; DRUG INTERACTION; DRUG SCREENING; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MULTICENTER STUDY (TOPIC); ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTICENTER STUDIES AS TOPIC; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PREGNANCY; PREGNANCY COMPLICATIONS; SIROLIMUS;

EID: 78650471578     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (311)

1. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 356 (9225): 194-202, 2000.
2. Kahan BD: Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 35 (3 Supl.): S37-S51, 2003.
3. MacDonald AS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71 (2): 271-280, 2001.
4. Blum CB: Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2 (6): 551-559, 2002.
5. Ducloux D, Kazory A, Chalopin JM: Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 66 (1): 441-447, 2004.
6. Anavekar NS, McMurray JJV, Velázquez EJ, Solomon SD, Kober L, Rouleau J-L y cols.: Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction. N Engl J Med 351 (13): 1285-1295, 2004.
7. Meier-Kriesche HU, Baliga R, Kaplan B: Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75 (8): 1291-5, 2003.
8. Fellstrom B, Jardine AG, Soveri I, Cole E, Gronhagen-Riska C, Neumayer HH y cols.: Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 79 (9): 1160-1163, 2005.
9. Chueh SC, Kahan BD: Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 76 (2): 375-382, 2003.
10. Legendre C, Campistol JM, Squifflet JP, Burke JT: Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc 35 (3 Supl.): S151-S153, 2003.
11. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroiani B y cols.: Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74 (8): 1070-1076, 2002.
12. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ y cols.: Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43 (8): 1170-1180, 2002.
13. Hoogeveen RC, Ballantyne CM, Pownall HJ, Opekun AR, Hachey DL, Jaffe JS y cols.: Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 72 (7): 1244-1250, 2001.
14. Massy ZA, De Bandt JP, Morelon E, Thevenin M, Lacour B, Kreis H. Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A. Nephrol Dial Transplant 15 (6): 928, 2000.
15. Elloso MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA y cols.: Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo e-deficient mice. Am J Transplant 3 (5): 562-569, 2003.
16. Podder H, Stepkowski SM, Napoli KL, Clark J, Verani RR, Chou TC y cols.: Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 12 (5): 1059-1071, 2001.
17. Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg K: Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transplant 18 (6): 642-646, 2004.
18. Kasiske B, Guijarro C, Massy Z, Wiederkehr M, Ma J: Cardiovascular disease after renal transplantation. J Am Soc Nephrol 7 (1): 158-165, 1996.
19. Schena FP, Jamieson N, Colon J, Shoker A, Pena J, Martínez J y cols.: FAVORABLE CARDIOVASCULAR RISK PROFILE WHEN SIROLIMUS IS USED WITHOUT CYCLOSPORINE COMPARED TO COMBINATION THERAPY: 3-YEAR RESULTS OF THE RAPAMUNE MAINTENANCE REGIMEN TRIAL. En: Am J Transplant; 2003; American Transplant Congress, Washington, DC, May 30-June 4, 2003; 2003.
20. Araki M, Flechner SM, Ismail HR, Flechner LM, Zhou L, Derweesh IH y cols.: Posttransplant Diabetes Mellitus in Kidney Transplant Recipients Receiving Calcineurin or mTOR Inhibitor Drugs. Transplantation 81 (3): 335-341, 2006.
21. Teutonico A, Schena PF, Di Paolo S: Glucose Metabolism in Renal Transplant Recipients: Effect of Calcineurin Inhibitor Withdrawal and Conversion to Sirolimus. J Am Soc Nephrol (10): 3128-3135, 2005.
22. Havrdova T, Saudek F, Boucek P, Adamec M, Koznarova R, Jedinakova T y cols.: Metabolic effect of sirolimus versus mycophenolate mofetil on pancreatic graft function in the early posttransplant period. Transplant Proc 37 (8): 3544-2545, 2005.
23. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M y cols.: Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature (7005): 200-205, 2004.
24. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167 (3): 399-403, 2004.
25. Khamzina L, Veilleux A, Bergeron S, Marette A: Increased Activation of the Mammalian Target of Rapamycin Pathway in Liver and Skeletal Muscle of Obese Rats: Possible Involvement in Obesity-Linked Insulin Resistance. Endocrinology (3): 1473-1481, 2005.
26. Swinford RD, Sorof JM, Braun MC, Kahan BD, Portman RJ: Sirolimus decreases body mass index in children post kidney transplantation. En: Journal of the American Society of Nephrology; 2002; 35th Annual Meeting, american society of Nephrology, October 30-November 4. p. 569A-570A, 2002.
27. Egidi MF, Cowan PA, Naseer A, Gaber AO: Conversion to sirolimus in solid organ transplantation: a Single-Center experience. Transplant Proc 35 (3 Supl.): S131-S137, 2003.
28. Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andrés V: Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27Kip1-independent pathway. Atherosclerosis (1): 31-38, 2004.
29. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S y cols.: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99 (16): 2164-2170, 1999.
30. Ikonen TS, Gummert JF, Hayase M, Honda Y, Hausen B, Christians U y cols.: Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 70 (6): 969-975, 2000.
31. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ y cols.: Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107 (12): 1664-70, 2003.
32. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T y cols.: Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload. Circulation 109 (24): 3050-3055, 2004.
33. Varghese Z, Fernando R, Moorhead JF, Powis SH, Ruan XZ: The effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipidmediated injury in renal allografts. Am J Physiol Renal Physiol (1): F43-F48, 2005.
34. Friend P, Legendre C, Daloze P, Colon J, Chapman J, Pena J y cols.: AN EVALUATION OF CARDIOVASCULAR RISK FACTORS ASSOCIATED WITH LONG-TERM SIROLIMUS (RAPAMUNE®) IMMUNOTHERAPY USED WITH OR WITHOUT CYCLOSPORINE. En: Transplantation; 2002; XIX International congress of The Transplantation Society, Miami, USA, August 25-30, 2002; p. 132, 2002.
35. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP y cols.: Long-Term Benefits with Sirolimus-Based Therapy after Early Cyclosporine Withdrawal. J Am Soc Nephrol 15 (3): 809-817, 2004.
36. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC y cols.: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen study. Transplantation 76 (2): 364-370, 2003.
37. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (5): 777-786, 2001.
38. Grinyo JM, Campistol JM, Paul J, García-Martínez J, Morales JM, Prats D y cols.: Pilot Randomized Study of Early Tacrolimus Withdrawal from a Regimen with Sirolimus Plus Tacrolimus in Kidney Transplantation. Am J Transplant 4 (8): 1308-1314, 2004.
39. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 5 (7): 1748-56, 2005.
40. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A, O'Driscoll G y cols.: Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 Years. A Randomized Clinical Trial. Circulation 110 (17): 2694-2700, 2004.
41. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E y cols.: Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy. Circulation 108: 48-53, 2003.
42. Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D y cols.: Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions The Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 44 (7): 1386-1392, 2004.
43. Hausleiter J, Kastrati A, Mehilli J, Vogeser M, Zohlnhofer D, Schuhlen H y cols.: Randomized, double-blind, placebocontrolled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 110 (7): 790-795, 2004.
44. Rodríguez AE, Rodríguez Alemparte M, Vigo CF, Fernández Pereira C, Llaurado C, Vetcher D y cols.: Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). Heart 91 (11): 1433-1437, 2005.
45. Brara PS, Moussavian M, Grise MA, Reilly JP, Fernández M, Schatz RA y cols.: Pilot Trial of Oral Rapamycin for Recalcitrant Restenosis. Circulation 107: 1722-1724, 2003.
46. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (19): 2486-2497, 2001.
47. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 45 (3 Pt 2): 16-153, 2005.
48. FDA. Rapamune-US-Summary of Product Characterisitics. [cited 2005 2005, Jun 1st]; Available from: http: //www.fda.gov/cder/foi/label/2005/21083s019,21110s024lbl .pdf
49. EMEA. Rapamune-EU-Summary of Product Characterisitics. [cited 2005 2005, May 18th]; Available from: http: //www.emea.eu.int/humandocs/Humans/EPAR/rapamune/rapamune. htm
50. Josef F, Marina K, Alois W: Sirolimus myopathy. Transplantation (12): 1773-1774, 2003.
51. Ciancio G, Burke GW, Gaynor JJ, Mattiazzi A, Roth D, Kupin W y cols.: A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. Ii. Survival, function, and protocol compliance at 1 year. Transplantation (2): 252-258, 2004.
52. Russ G, Segoloni G, Oberbauer R, Legendre C, Mota A, Eris J y cols.: Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function. Transplantation (9): 1204-1211, 2005.
53. Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE: Comparative Effects of Sirolimus and Mycophenolate Mofetil on Erythropoiesis in Kidney Transplant Patients. Am J Transplant 4 (12): 2001-2006, 2004.
54. Anil Kumar MS, Heifets M, Fyfe B, Saaed MI, Moritz MJ, Parikh MH y cols.: Comparison of Steroid Avoidance in Tacrolimus/ Mycophenolate Mofetil and Tacrolimus/Sirolimus Combination in Kidney Transplantation Monitored by Surveillance Biopsy. Transplantation 80 (6): 807-814, 2005.
55. Kim M-J, Mayr M, Pechula M, Steiger J, Dickenmann M: Marked erythrocyte microcytosis under primary immunosuppression with sirolimus. Transplant International 19 (1): 12-18, 2006.
56. Hamdy AF, El-Agroudy AE, Bakr MA, Mostafa A, El-baz M, El-Shahawy E-M y cols.: Comparison of Sirolimus with Low-Dose Tacrolimus Versus Sirolimus-based Calcineurin Inhibitor-Free Regimen in Live Donor Renal Transplantation. American Journal of Transplantation 5 (10): 2531-2538, 2005.
57. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR y cols.: Complete Avoidance of Calcineurin Inhibitors in Renal Transplantation: a Randomized Trial Comparing Sirolimus and Tacrolimus. American Journal of Transplantation (3): 514-522, 2006.
58. Thaunat O, Beaumont C, Chatenoud L, Lechaton S, Mamzer-Bruneel MF, Varet B y cols.: Anemia after Late Introduction of Sirolimus May Correlate with Biochemical Evidence of a Chronic Inflammatory State. Transplantation 80 (9): 1212-1219, 2005.
59. Cahill BC, Somerville KT, Crompton JA, Parker ST, O'Rourke MK, Stringham JC y cols.: Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant 22 (2): 169-176, 2003.
60. Maiorano AM, Schena A, Stallone G, Infante G, Pontrelli P, Verrienti R y cols.: RAPAMYCIN INTERFERES WITH IRON METABOLISM IN RENAL TRANSPLANT RECIPIENTS. En; 2005; XLII ERA-EDTA Congress, June 4-7, 2005, Istambul (Turkey); 2005.
61. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM: Predictors of Success in Conversion from Calcineurin Inhibitor to Sirolimus in Chronic Allograft Dysfunction. Am J Transplant 4 (11): 1869-1875, 2004.
62. Van Biesen W, Vanholder R, Veys N, Verbeke F, Lameire N: Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation (3): 367-368, 2005.
63. Jaster R, Bittorf T, Klinken SP, Brock J: Inhibition of proliferation but not erythroid differentiation of J2E cells by rapamycin. Biochem Pharmacol 51 (9): 1181-1185, 1996.
64. Bouscary D, Pene F, Claessens YE, Muller O, Chretien S, Fontenay-Roupie M y cols.: Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 101 (9): 3436-3443, 2003.
65. Buchler M, Lebranchu Y, Beneton M, Le Meur Y, Heng AE, Westeel PF y cols.: Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clinical Pharmacology & Therapeutics 78 (1): 34-42, 2005.
66. Renders L, Steinbach R, Valerius T, Schocklmann HO, Kunzendorf U: Low-Dose Sirolimus in Combination with Mycophenolate Mofetil Improves Kidney Graft Function Late after Renal Transplantation and Suggests Pharmacokinetic Interaction of Both Immunosuppressive Drugs. Kidney Blood Press Res 27 (3): 181-185, 2004.
67. Cattaneo D, Merlini S, Zenoni S, Baldelli S, Gotti E, Remuzzi G y cols.: Influence of co-medication with sirolimus or cyclosporine on mycophenolic Acid pharmacokinetics in kidney transplantation. Am J Transplant 5 (12): 2937-2944, 2005.
68. Picard N, Premaud A, Rousseau A, Le Meur Y, Marquet P. A comparison of the effect of cyclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. British Journal of Clinical Pharmacology in press.
69. El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C y cols.: Pharmacokinetics of Mycophenolic Acid in Kidney Transplant Patients Receiving Sirolimus Versus Cyclosporine. Transplantation Proceedings 37 (2): 864-866, 2005.
70. Hong JC, Kahan BD: Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 69 (10): 2085-2090, 2000.
71. Quesniaux VF, Wehrli S, Steiner C, Joergensen J, Schuurman HJ, Herrman P y cols.: The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 84 (5): 1543-1552, 1994.
72. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC: Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 42 (5): 1058-1068, 2003.
73. Langer RM, Van Buren CT, Katz SM, Kahan BD: De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination. Transplantation 73 (5): 756-760, 2002.
74. Robson M, Cote I, Abbs I, Koffman G, Goldsmith D: Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 3 (3): 324-327, 2003.
75. Paramesh AS, Grosskreutz C, Florman SS, Gondolesi GE, Sharma S, Kaufman SS y cols.: Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation (1): 129-148, 2004.
76. Saikali JA, Truong LD, Suki WN: Sirolimus may promote thrombotic microangiopathy. Am J Transplant 3 (2): 229-230, 2003.
77. Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E y cols.: Sirolimus and Thrombotic Microangiopathy after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 11 (7): 551-557, 2005.
78. Fortin MC, Raymond MA, Madore F, Fugere JA, Paquet M, St-Louis G y cols.: Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant 4 (6): 946-952, 2004.
79. Barone GW, Gurley BJ, Abul-Ezz SR, Gokden N: Sirolimusinduced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis 42 (1): 202-206, 2003.
80. Florman S, Benchimol C, Lieberman K, Burrows L, Bromberg JS: Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen. Pediatr Transplant 6 (4): 352-355, 2002.
81. Crew RJ, Radhakrishnan J, Cohen DJ, Stern L, Goldstein M, Hardy M y cols.: De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrol Dial Transplant 20 (1): 203-209, 2005.
82. Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E y cols.: Sirolimus-Induced Thrombotic Microangiopathy is Associated with Decreased Expression of Vascular Endothelial Growth Factor in Kidneys. Am J Transplant (10): 2441-2447, 2005.
83. Pelle G, Xu Y, Khoury N, Mougenot B, Rondeau E: Thrombotic microangiopathy in marginal kidneys after sirolimus use. Am J Kidney Dis 46 (6): 1124-1128, 2005.
84. Gutiérrez de la Fuente C, Sola E, Alférez MJ, Navarro A, Cabello M, Burgos D y cols.: De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period. Nefrologia 24 Supl. 3: 3-6, 2004.
85. Yango A, Morrissey P, Monaco A, Butera J, Gohh RY. Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange. Clin Nephrol 58 (1): 77-78, 2002.
86. Franco A, Hernández D, Capdevilla L, Errasti P, González M, Ruiz JC y cols.: De novo Hemolytic-Uremic Syndrome/ Thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplant Proc 35 (5): 1764-1766, 2003.
87. Edwards C, House A, Shahinian V, Knoll G: Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy. Nephrol Dial Transplant 17 (8): 1524-1526, 2002.
88. Heering P, Deppe CE, Farokhzad F, Helmchen U, Grabensee B: Hemolytic uremic syndrome after renal transplantation: immunosuppressive therapy with rapamycin. Nephron (1): 177, 2002.
89. Ibañez JP, Monteverde ML, Goldberg J, Díaz MA, Turconi A: Sirolimus in Pediatric Renal Transplantation. Transplantation Proceedings 37 (2): 682-684, 2005.
90. Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ: Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant 18 Supl. 12: 61-66, 2004.
91. Oyen O, Strom EH, Midtvedt K, Bentdal O, Hartmann A, Bergan S y cols.: Calcineurin Inhibitor-Free Immunosuppression in Renal Allograft Recipients with Thrombotic Microangiopathy/ Hemolytic Uremic Syndrome. American Journal of Transplantation 6 (2): 412-418, 2006.
92. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P y cols.: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67 (7): 1036-1042, 1999.
93. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J y cols.: Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 18 (1): 22-28, 2005.
94. Cutler C, Antin JH: Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant (6): 471-476, 2004.
95. Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker M, First R y cols.: A RANDOMIZED, PROSPECTIVE, MULTICENTER COMPARISON OF TACROLIMUS (TAC), MYCOPHENOLATE MOFETIL (MMF) AND STEROIDS VS CYCLOSPORINE MICROEMULSION, MMF AND STEROIDS VS TAC, SIROLIMUS AND STEROIDS IN DE NOVO CARDIAC TRANSPLANT RECIPIENTS 12 MONTH REPORT. In: Am J Transplant; 2005; American Transplant Congress, Seattle; 2005.
96. Trotter JF, Wallack A, Steinberg T: Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper. Transplant Infect Dis 5 (4): 174-180, 2003.
97. Kahan BD: Sirolimus: a ten-year perspective. Transplantation Proceedings 36 (1): 71-75, 2004.
98. Ozaki KS, Camara NOS, Galante NZ, Camargo LFA, Pacheco-Silva A: Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients. International Immunopharmacology 5 (1): 103-106, 2005.
99. Egidi MF, Lo A, Mya M, Gaber LW, Lau K, Shokouh-Amiri MH y cols.: LONG-TERM RESULTS IN SOLID ORGAN TRANSPLANT RECIPIENTS CONVERTED FROM CALCINEURIN-INHIBITORS TO SIROLIMUS. En: Transplantation; July, 27th; XX International Congress of the Transplantation Society; 2004.
100. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA y cols.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 (9): 847-858, 2003.
101. Vitko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y y cols.: Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78 (10): 1532-1540, 2004.
102. Ozaki KS, Nogueira E, Camargo LFA, Granato C, Melaragno C, Camara NOS y cols.: CO-ADJUVANT USE OF SIROLIMUS FOR TREATMENT OF GANCYCLOVIR-INDUCED RESISTANT CYTOMEGALOVIRUS INFECTION IN TRANSPLANT PATIENTS. En: Am J Transplant; 2005; American Transplant Congress, Seattle; 2005.
103. Deborska D, Durlik M, Sadowska A, Nowacka-Cieciura E, Pazik J, Lewandowski Z y cols.: Human herpesvirus-6 in renal transplant recipients: potential risk factors for the development of human herpesvirus-6 seroconversion. Transplant Proc 35 (6): 2199-2201, 2003.
104. Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM: Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 63 (15: 4472-4480, 2003.
105. McDonald RA, McIntosh M, Stablein D, Grimm P, Wyatt R, Arar M y cols.: INCREASED INCIDENCE OF PTLD IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS ENROLLED IN A RANDOMIZED CONTROLLED TRIAL OF STEROID WITHDRAWAL: A STUDY OF THE CCTPT. En: Am J Transplant; 2005; American Transplant Congress, Seattle; 2005.
106. Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK y cols.: Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV {beta}-chemokines: an approach to suppress R5 strains of HIV-1. PNAS 100 (18): 10411-10416, 2003.
107. Castedo M, Ferri KF, Blanco J, Roumier T, Larochette N, Barretina J y cols.: Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation. J Exp Med 194 (8): 1097-1110, 2001.
108. Perfettini J-L, Roumier T, Castedo M, Larochette N, Boya P, Raynal B y cols.: NF-{kappa}B and p53 Are the Dominant Apoptosis-inducing Transcription Factors Elicited by the HIV-Envelope. J Exp Med 199 (5): 629-640, 2004.
109. Kumar MSA, Sierka DR, Damask AM, Fyfe B, MCalack RF, Heifets M y cols.: Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 67 (4): 1622-1629, 2005.
110. Jain AK, Venkataramanan R, Fridell JA, Gadomski M, Shaw LM, Ragni M y cols.: Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl 8 (9): 838-840, 2002.
111. Izzedine H, Launay-Vacher V, Baumelou A, Deray G: Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 66 (2): 532-541, 2004.
112. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R y cols.: Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 117 (5): 1198-204, 1999.
113. Biecker E, De Gottardi A, Neef M, Unternahrer M, Schneider V, Ledermann M y cols.: Long-Term Treatment of Bile Duct-Ligated Rats with Rapamycin (Sirolimus) Significantly Attenuates Liver Fibrosis: Analysis of the Underlying Mechanisms. J Pharmacol Exp Ther 313 (3): 952-961, 2005.
114. Forman LM, Kam I, Everson GT: MAINTENANCE OF EXCELLENT PATIENT SURVIVAL AFTER LIVER TRANSPLANTATION FOR CHRONIC HEPATITIS C IN A SINGLE CENTER DURING THREE ERAS OF IMMUNOSUPPRESSION CHARACTERIZED BY WIDE VARIATION IN USE OF OKT3. En: Am J Transplant; 2004; American Transplant Congress, May 14-19, 2004, Boston, MA; 2004.
115. Samonakis DN, Cholongitas E, Triantos CK, Griffiths P, Dhillon AP, Thalheimer U y cols.: Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantion for HCV cirrhosis. Journal of Hepatology (4): 386-395, 2005.
116. Wali RK, Drachenberg C, Hirsch HH, Papadimitriou J, Nahar A, Mohanlal V y cols.: BK Virus-Associated Nephropathy in Renal Allograft Recipients: Rescue Therapy by Sirolimus-Based Immunosuppression. Transplantation 78 (7): 1069-1073, 2004.
117. Hirsch HH, Mohaupt M, Klimkait T: Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy. J Infect Dis 184 (11): 1494-1496, 2001.
118. Lipshutz GS, Flechner SM, Govani MV, Vincenti F: BK Nephropathy in Kidney Transplant Recipients Treated with a Calcineurin Inhibitor-Free Immunosuppression Regimen. Am J Transplant 4 (12): 2132-2134, 2004.
119. Singh N, Heitman J: Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation 77 (6): 795-800, 2004.
120. Wong GK, Griffith S, Kojima I, Demain AL: Antifungal activities of rapamycin and its derivatives, prolylrapamycin, 32-desmethylrapamycin, and 32-desmethoxyrapamycin. J Antibiot (Tokyo) 51 (5): 487-491, 1998.
121. Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS: Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 51 (2): 313-316, 2003.
122. Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB: Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy 26 (2): 289-295, 2006.
123. Thomas PP, Manivannan J, John GT, Jacob CK: Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation 77 (3): 474-475, 2004.
124. Cervelli MJ: Fluconazole-sirolimus drug interaction. Transplantation (10): 1477-1478, 2002.
125. Kahan BD, Julián BA, Pescovitz MD, Vanrenterghem Y, Neylan J: Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 68 (10): 1526-1532, 1999.
126. Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE y cols.: Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 67 (4): 505-509, 1999.
127. Domínguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS: Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 70 (8): 1244-1247, 2000.
128. Fisher A, Seguel JM, De La Torre AN, Wilson D, Merchant A, Arora RK y cols.: Effect of sirolimus on infection incidence in liver transplant recipients. Liver Transpl 10 (2): 193-198, 2004.
129. Gonwa T, Méndez R, Yang HC, Weinstein S, Jensik S, Steinberg S: Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 75 (8): 1213-1220, 2003.
130. Gómez-Cambronero J: Rapamycin inhibits GM-CSF-induced neutrophil migration. FEBS Lett 550 (1-3): 94-100, 2003.
131. Jorgensen PF, Wang JE, Almlof M, Solberg R, Okkenhaug C, Scholz T y cols.: Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scand J Immunol 53 (2): 184-191, 2001.
132. Bottiger Y, Brattstrom C, Backman L, Claesson K, Burke JT: Trimethoprim-sulphamethoxazole does not affect the pharmacokinetics of sirolimus in renal transplant recipients. British Journal of Clinical Pharmacology 60 (5): 566-569, 2005.
133. Mahe E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF y cols.: Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1. Transplantation (4): 476-482, 2005.
134. Stallone G, Infante B, Di Paolo S, Schena A, Grandaliano G, Gesualdo L y cols.: Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transplant 19 (11: 2906-2908, 2004.
135. Burdese M, Rossetti M, Guarena C, Consiglio V, Mezza E, Soragna G y cols.: Sirolimus and ACE-Inhibitors: A Note of Caution. Transplantation 79 (2): 251-252, 2005.
136. Mohaupt MG, Vogt B, Frey FJ: Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation 72 (1): 162-164, 2001.
137. Wadei H, Gruber SA, El-Amm JM, Garnick J, West MS, Granger DK y cols.: Sirolimus-induced angioedema. Am J Transplant 4 (6): 1002-1005, 2004.
138. Aboujaoude W, Milgrom ML, Govani MV: Lymphedema associated with sirolimus in renal transplant recipients 1. Transplantation 77 (7): 1094-1096, 2004.
139. Romagnoli J, Citterio F, Nanni G, Tondolo V, Castagneto M: Severe Limb Lymphedema in Sirolimus-Treated Patients. Transplantation Proceedings 37 (2): 834-836, 2005.
140. Fuchs U, Zittermann A, Berthold HK, Tenderich G, Deyerling KW, Minami K y cols.: Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 79 (8): 981-983, 2005.
141. Ram Peddi V, Jensik S, Pescovitz M, Pirsch J, Adler SH, Richard Thistlethwaite J y cols.: An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transpl 19 (1): 130-136, 2005.
142. Watson CJE, Firth J, Williams PF, Bradley JR, Pritchard N, Chaudhry A y cols.: A Randomized Controlled Trial of Late Conversion from CNI-Based to Sirolimus-Based Immunosuppression Following Renal Transplantation. American Journal of Transplantation 5 (10): 2496-2503, 2005.
143. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, the Sirolimus Renal Function Study Group: Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 74 (11: 1560-1567, 2002.
144. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM: Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 50 (4): 1110-1117, 1996.
145. Reitamo S, Spuls P, Sassolas B, Lahfa M, Claudy A, Griffiths CE: Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145 (3): 438-445, 2001.
146. Andoh TF, Lindsley J, Franceschini N, Bennett WM: Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 62 (3): 311-316, 1996.
147. Lloberas N, Alperovich G, Torras J, Herrero-Fresneda I, Riera M, Franquesa M y cols.: The Association of Rapamycin Either with FK506 or Cyclosporine Produce a Different Functional and Structural Pattern of Nephrotoxicity. En: J Am Soc Nephrol; 2003; American Society of Nephrology. Renal Week 2003. San Diego, November 12-17, 2003; 2003.
148. Trotter JF: Sirolimus in liver transplantation. Transplant Proc (3 Supl.): S193-S200, 2003.
149. Trotter JF, Bak T, Pearson M, Wachs M, Kugelmas M, Kam I y cols.: Nephrotoxicity is more common with cyclosporine A than tacrolimus in liver transplant recipients receiving sirolimus as primary immunosuppression. En: Liver Transpl; 2002, p. C18.
150. Saeed MI, Kumar MSA, Heifets M, Sierka D, Xiao SG, Moritz MJ y cols.: COMPARISON OF TACROLIMUS (TAC) AND SIROLIMUS (SLR) VERSUS CYCLOSPORINE (CSA) AND SLR IN KIDNEY TRANSPLANT RECIPIENTS MAINTAINED ON STEROID FREE IMMUNOSUPPRESSION. En: Am J Transplant; 2004; American Transplant Congress, May 14-19, 2004, Boston, MA; 2004.
151. Méndez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S: A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 80 (3): 303-309, 2005.
152. Vitko S, Wlodarczyk Z, Kyllonen L, Czajkowski Z, Margreiter R, Backman L y cols.: Tacrolimus Combined with Two Different Dosages of Sirolimus in Kidney Transplantation: Results of a Multicenter Study. American Journal of Transplantation (3): 531-538, 2006.
153. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B: Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 5 (9): 2273-2280, 2005.
154. Radovancevic B, Vrtovec B: Sirolimus therapy in cardiac transplantation. Transplant Proc 35 (3 Supl.): S171-S176, 2003.
155. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D y cols.: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69 (7): 1252-1260, 2000.
156. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A y cols.: Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2 (5): 436-442, 2002.
157. Bonegio RGB, Fuhro R, Wang Z, Valeri CR, Andry C, Salant DJ y cols.: Rapamycin Ameliorates Proteinuria-Associated Tubulointerstitial Inflammation and Fibrosis in Experimental Membranous Nephropathy. J Am Soc Nephrol 16 (7): 2063-2072, 2005.
158. Alperovich G, Lloberas N, Torras J, Rama I, Rama I, la Franquesa M y cols.: AMELIORATION OF LUPUS NEPHRITIS WITH RAPAMYCIN IN A MURINE MODEL. En: 2005; XLII ERA-EDTA Congress, June 4-7, 2005, Istambul (Turkey); 2005.
159. Piñera C, Ramos A, Buelta L, De Cos MA, Setién MA, Merino R y cols.: EFECTO DE RAPAMICINA EN LA PREVENCIÓN DE LA NEFROPATíA LúPICA DEL MODELO DE LUPUS MURINO NZB/WF1. En: Nefrologia; 2004; Congreso de la SEN, Tenerife, 2-6 Octubre de 2004; 2004.
160. Legendre C, Ruiz JC, Claesson K, Oberbauer R, Mota A, Eris J y cols.: EARLY CYCLOSPORINE WITHDRAWAL WITH SIROLIMUS MAINTENANCE THERAPY IN THE PRESENCE OF RISK FACTORS FOR REDUCED RENAL FUNCTION: 5-YEAR RESULTS FROM THE RAPAMUNE MAINTENANCE REGIMEN (RMR) TRIAL. En: Transplant Int; 2005; ESOT, Geneve 2005; 2005.
161. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H y cols.: De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at Two Years. Am J Transplant 4 (11): 1776-1785, 2004.
162. Morales JM, Grinyo JM, Campistol JM, García J, Arias M, Paul J y cols.: FK-506 WITHDRAWAL FROM A REGIMEN OF SIROLIMUS PLUS FK-506 RESULTS AT 2-YEARS IN AN IMPROVEMENT IN BLOOD PRESSURE AND RENAL FUNCTION WITHOUT PROTEINURIA IN ONGOING KIDNEY RECIPIENTS. En: Transplant Int; 2005; ESOT congress 2005, Geneve; 2005.
163. Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G y cols.: 6 MONTHS PRELIMINARY RESULTS OF A RANDOMIZED TRIAL COMPARING SIROLIMUS (SRL) VERSUS TACROLIMUS (FK) IN 141 TRANSPLANT PATIENTS RECEIVING A CADAVERIC RENAL GRAFT. En: Am J Transplant; 2005; American Transplant Congress, Seattle; 2005.
164. Lebranchu Y, Buchler M, Etienne I, Toupance O, Westell PF, Legendre C y cols.: 12 MONTH RESULTS OF A RANDOMIZED TRIAL COMPARING SIROLIMUS (SRL) VERSUS CYCLOSPORINE (CsA) IN 150 TRANSPLANT PATIENTS RECEIVING A CADAVERIC RENAL GRAFT. En: Am J Transplant; 2005; American Transplant Congress, Seattle; 2005.
165. Morelon E, Kreis H: Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 35 (3 Supl.): S52-S57, 2003.
166. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C: Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 80 (9): 1198-1203, 2005.
167. Dervaux T, Caillard S, Meyer C, Ellero B, Woehl-Jaegle ML, Hannedouche T y cols.: Is sirolimus responsible for proteinuria? Transplant Proc 37 (6): 2828-2829, 2005.
168. Aliabadi A, Kammersta, X, Tter D, Seebacher G, Ro y cols.: 242: Development of proteinuria after switch to sirolimus based immunosuppression in long-term cardiac transplant patients. The Journal of Heart and Lung Transplantation 25 (2, Supl. 1): 128, 2006.
169. Senior PA, Paty BW, Cockfield SM, Ryan EA, Shapiro AM: Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 5 (9): 2318-2323, 2005.
170. Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E: Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 17 (4): 215-220, 2004.
171. Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen D, Verpooten GA: Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 80 (11): 1578-1585, 2005
172. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J y cols.: Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 (11: 2517-2523, 2005.
173. Butani L: Investigation of Pediatric Renal Transplant Recipients with Heavy Proteinuria after Sirolimus Rescue. Transplantation (9): 1362-1366, 2004.
174. Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N y cols.: Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 21 (2): 488-493, 2006.
175. Straathof-Galema L, Wetzels JFM, Dijkman HBPM, Steenbergen EJ, Hilbrands LB: Sirolimus-Associated Heavy Proteinuria in a Renal Transplant Recipient: evidence for a Tubular Mechanism. American Journal of Transplantation 6 (2): 429-433, 2006.
176. Izzedine H, Brocheriou I, Frances C: Post-Transplantation Proteinuria and Sirolimus. N Engl J Med 353 (19): 2088-a-2089, 2005.
177. Daniel C, Renders L, Amann K, Schulze-Lohoff E, Hauser IA, Hugo C: Mechanisms of Everolimus-Induced Glomerulosclerosis After Glomerular Injury in the Rat. American Journal of Transplantation 5 (12): 2849-2861, 2005.
178. Fervenza FC, Fitzpatrick PM, Mertz J, Erickson SB, Liggett S, Popham S y cols.: Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 19 (5): 1288-1292, 2004.
179. Patel P, Pal S, Ashley C, Sweny P, Burns A: Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506 in treatment of refractory minimal change nephropathy, a clinical case report. Nephrol Dial Transplant 20 (5): 985-987, 2005.
180. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A: A Prospective, Open-Label Trial of Sirolimus in the Treatment of Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol in press: CJN.00120605.
181. Hong JC, Kahan BD: A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation (9): 1320-1328, 2001.
182. Knight RJ, Kerman RH, Schoenberg L, Podder H, Van Buren CT, Katz S y cols.: The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 78 (6): 904-910, 2004.
183. Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL y cols.: A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant 14 (6): 550-554, 2000.
184. Pescovitz MD, Govani M: Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis 38 (4 Supl. 2: S16-S21, 2001.
185. Mital D, Podlasek W, Jensik S: Sirolimus-based steroid-free maintenance immunosuppression. Transplant Proc 34 (5): 1709, 2002.
186. El-Sabrout R, Delaney V, Qadir M, Butt F, Hanson P, Butt KM: Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients-a single center experience. Transplant Proc 35 (3 Supl.): S89-S94, 2003.
187. Shaffer D, Langone A, Nylander WA, Goral S, Kizilisik AT, Helderman JH: A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. Clin Transplant (Supl. 9): 31-34, 2003.
188. Vincenti F, Stock P: De novo use of sirolimus in immunosuppression regimens in kidney and kidney-pancreas transplantation at the University of California, San Francisco. Transplant Proc 35 (3 Supl.): S183-S186, 2003.
189. Lieberthal W, Fuhro R, Andry CC, Rennke H, Abernathy VE, Koh JS y cols.: Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281 (4): F693-706, 2001.
190. McTaggart RA, Gottlieb D, Brooks J, Bacchetti P, Roberts JP, Tomlanovich S y cols.: Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 3 (4): 416-423, 2003.
191. McTaggart RA, Tomlanovich S, Bostrom A, Roberts JP, Feng S: Comparison of Outcomes after Delayed Graft Function: Sirolimus-Based Versus Other Calcineurin-Inhibitor Sparing Induction Immunosuppression Regimens. Transplantation 78 (3): 475-480, 2004.
192. Smith KD, Wrenshall LE, Nicosia RF, Pichler R, Marsh CL, Alpers CE y cols.: Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 14 (4): 1037-1045, 2003.
193. Lo A, Egidi MF, Gaber L, Amiri HS, Vera S, Gross B y cols.: DELAYED GRAFT FUNCTION AND SIROLIMUS. En: Am J Transplant; 2004; American Transplant Congress, May 14 -19, 2004, Boston, MA; 2004.
194. Derweesh IH, Flechner SM, Moneim HA, Zhou L, Araki M, Modlin C y cols.: COMPARISON OF DENOVO SIROLIMUS VS CALCINEURIN INHIBITOR IMMUNOSUPPRESSION ON EARLY FUNCTIONAL RECOVERY OF KIDNEY TRANSPLANTS. En: Am J Transplant; 2005; American Transplant Congress, Seattle; 2005.
195. Stallone G, Di Paolo S, Schena A, Infante B, Battaglia M, Ditonno P y cols.: Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol 15 (1): 228-33, 2004.
196. Knechtle SJ, Pirsch JD, J HF, Becker BN, Friedl A, Colvin RB y cols.: Campath-1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: results of a Pilot Study. Am J Transplant 3 (6): 722-730, 2003.
197. Hong JC, Kahan BD: Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation 68 (5): 701-704, 1999.
198. Lo A, Egidi MF, Gaber LW, Amiri HS, Vera S, Nezakatgoo N y cols.: Comparison of Sirolimus-Based Calcineurin Inhibitor-Sparing and Calcineurin Inhibitor-Free Regimens in Cadaveric Renal Transplantation. Transplantation 77 (8): 1228-1235, 2004.
199. Guba M, Yezhelyev M, Eichhorn ME, Schmid G, Ischenko I, Papyan A y cols.: Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (11): 4463-4469, 2005.
200. Wiesner R, Klintmalm GB, McDiarmid S, and the Rapamune Liver Transplant Study Group. SIROLIMUS IMMUNOTHERAPY RESULTS IN REDUCED RATES OF ACUTE REJECTION IN DE NOVO ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS. En: American Journal of Transplantation; 2002; Washington; 2002.
201. Jain A, Costa G, Marsh W, Fontes P, Devera M, Mazariegos G y cols.: Thrombotic and nonthrombotic hepatic artery complications in adults and children following primary liver transplantation with long-term follow-up in 1,000 consecutive patients. Transpl Int 19 (1): 27-37, 2006.
202. Oh CK, Pelletier SJ, Sawyer RG, Dacus AR, McCullough CS, Pruett TL y cols.: Uni-and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation. Transplantation 71 (6): 767-772, 2001.
203. Stange BJ, Glanemann M, Nuessler NC, Settmacher U, Steinmuller T, Neuhaus P: Hepatic artery thrombosis after adult liver transplantation. Liver Transpl 9 (6): 612-620, 2003.
204. Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T y cols.: Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 9 (5): 463-468, 2003.
205. Langer RM, Kahan BD: Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients. Transplantation 76 (2): 318-323, 2003.
206. Pascual M, Thadhani R, Laposata M, Williams WW, Farrell ML, Johnson SM y cols.: Anticardiolipin antibodies and hepatic artery thrombosis after liver transplantation. Transplantation (9): 1361-1364, 1997.
207. Collier JD, Sale J, Friend PJ, Jamieson NV, Calne RY, Alexander GJ: Graft loss and the antiphospholipid syndrome following liver transplantation. J Hepatol 29 (6): 999-1003, 1998.
208. Ducloux D, Pellet E, Fournier V, Rebibou JM, Bresson-Vautrin C, Racadot E y cols.: Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 67 (1): 90-93, 1999.
209. Schuetze SM, Linenberger M: Acquired protein S deficiency with multiple thrombotic complications after orthotopic liver transplant. Transplantation 67 (10): 1366-1369, 1999.
210. Stringer MD, Melissari E, Kakkar VV, Tan KC: Protein C deficiency and thrombotic complications after liver transplantation in children. Lancet 1 (8629): 102-103, 1989.
211. Gillis S, Lebenthal A, Pogrebijsky G, Levy Y, Eldor A, Eid A: Severe thrombotic complications associated with activated protein C resistance acquired by orthotopic liver transplantation. Haemostasis 30 (6): 316-320, 2000.
212. Tanyel FC, Ocal T, Balkanci F, Cekirge S, Senocak ME, Buyukpamukcu N y cols.: The factor V Leiden mutation: a possible contributor to the hepatic artery thrombosis encountered after liver transplantation in a child. J Pediatr Surg 35 (4): 607-609, 2000.
213. Solano C, Self MJ, Cobcroft RG: Liver transplant acquired activated protein C resistance presenting with deep vein thrombosis years after transplant. Blood Coagul Fibrinolysis (4): 325-326, 2001.
214. Wuthrich RP: Factor V Leiden mutation: potential thrombogenic role in renal vein, dialysis graft and transplant vascular thrombosis. Curr Opin Nephrol Hypertens 10 (3): 409-414, 2001.
215. Hocher B, Slowinski T, Hauser I, Vetter B, Fritsche L, Bachert D y cols.: Association of factor V Leiden mutation with delayed graft function, acute rejection episodes and longterm graft dysfunction in kidney transplant recipients. Thromb Haemost 87 (2): 194-198, 2002.
216. Leroy-Matheron C, Duvoux C, Van Nhieu JT, Leroy K, Cherqui D, Gouault-Heilmann M: Activated protein C resistance acquired through liver transplantation and associated with recurrent venous thrombosis. J Hepatol 38 (6): 866-869, 2003.
217. Willems M, Sterneck M, Langer F, Jung R, Haddad M, Hagel C y cols.: Recurrent deep-vein thrombosis based on homozygous factor V Leiden mutation acquired after liver transplantation. Liver Transpl 9 (8): 870-873, 2003.
218. De Mitrio V, Marino R, Rendina M, Di Bari L, Francavilla A, Schiraldi O: Is activated protein C resistance following orthotopic liver transplantation a risk factor for venous thrombosis? Blood Coagul Fibrinolysis 10 (4): 211-212, 1999.
219. Irish AB, Green FR, Gray DW, Morris PJ: The factor V Leiden (R506Q) mutation and risk of thrombosis in renal transplant recipients. Transplantation 64 (4): 604-607, 1997.
220. Wuthrich RP, Cicvara-Muzar S, Booy C, Maly FE: Heterozygosity for the factor V Leiden (G1691A) mutation predisposes renal transplant recipients to thrombotic complications and graft loss. Transplantation 72 (3): 549-550, 2001.
221. Ekberg H, Svensson PJ, Simanaitis M, Dahlback B: Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. Transplantation 69 (8): 1577-1581, 2000.
222. Mas VR, Fisher RA, G D, Wilkinson DS, Garrett CT, Ferreira-González A: Hepatic artery thrombosis after liver transplantation and genetic factors: prothrombin G20210A polymorphism. Transplantation 76 (1): 247-249, 2003.
223. Parker J, Pagliuca A, Kitiyakara T, Whitehead M, Heaton N, O'Grady J y cols.: Discrepancy between phenotype and genotype on screening for factor V Leiden after transplantation. Blood 97 (8): 2525-2526, 2001.
224. Van Gelder T, Ter Meulen CG, Hene R, Weimar W, Hoitsma A: Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 75 (6): 788-791, 2003.
225. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL y cols.: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343 (4): 230-238, 2000.
226. Mathew TH, Van Buren C, Kahan BD, Butt K, Hariharan S, Zimmerman JJ y cols.: A Comparative Study of Sirolimus Tablet Versus Oral Solution for Prophylaxis of Acute Renal Allograft Rejection. J Clin Pharmacol 46 (1): 76-87, 2006.
227. Langer RM, Kahan BD: Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation (6): 804-808, 2002.
228. Goel M, Flechner SM, Zhou L, Mastroianni B, Savas K, Derweesh I y cols.: The Influence of Various Maintenance Immunosuppressive Drugs on Lymphocele Formation and Treatment After Kidney Transplantation. J Urol 171 (5): 1788-1792, 2004.
229. Fahrni JA, Berry GJ, Morris RE, Rosen GD: Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation 63 (4): 533-537, 1997.
230. Adams BF, Berry GJ, Huang X, Shorthouse R, Brazelton T, Morris RE: Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts. Transplantation 69 (11: 2260-2266, 2000.
231. Dean PG, Lund WJ, Larson TS, Prieto M, Nyberg SL, Ishitani MB y cols.: Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77 (10): 1555-1561, 2004.
232. Kandaswamy R, Melancon JK, Dunn T, Tan M, Casingal V, Humar A y cols.: A prospective randomized trial of steroidfree maintenance regimens in kidney transplant recipientsan interim analysis. Am J Transplant 5 (6): 1529-1536, 2005.
233. Flechner SM, Zhou L, Derweesh I, Mastroianni B, Savas K, Goldfarb D y cols.: The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation (12): 1729-1734, 2003.
234. King-Biggs MB, Dunitz JM, Park SJ, Savik SK, Hertz MI: Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation (9): 1437-1443, 2003.
235. Bhorade SM, Ahya V, Kotloff R, Baz M, Valentine V, Arcasoy S y cols.: Six month results of sirolimus versus azathioprine in a tacrolimus based immunosuppressive regimen in lung transplantation. En: The Journal of Heart and Lung Transplantation; 2005 2005/2; ISHLT 25th anniversary meeting and scientfic sessions, April 5-9, 2005, Philadelphia Marriott; pp. S92-S93.
236. Stevens RB, Botha J, Grant W, Groggel G, Lane J, Wrenshall L: A SINGLE CENTER EXPERIENCE WITH STEROIDSPARING IMMUNOSUPPRESSION IN PANCREAS AND RENAL TRANSPLANTATION: THYMOGLOBULIN® INDUCTION WITH DELAYED USE OF RAPAMUNE® AND PROGRAF ®. En: Am J Transplant; 2004; American Transplant Congress, May 14-19, 2004, Boston, MA; 2004.
237. Kahan BD, Dejian L, Schoenberg L, Knight R, Katz S, Van Buren C: OUTCOMES OF 894 RENAL ALLOGRAFT RECIPIENTS TREATED DE NOVO WITH A SIROLIMUS-CYCLOSPORINE COMBINATION AND FOLLOWED FOR 1-8 YEARS. En: Transplantation; 2004 July, 27th; XX International Congress of the Transplantation Society; 2004.
238. Oppenheimer F, Saval N, Gutiérrez A, Campistol JM, Cofan F, Esforzado N y cols.: Experience with calcineurinic-free immunosuppression in kidney transplantation with marginal donors. En: Am J Transplant; 2005; American Transplant Congress, Seattle; 2005.
239. Tellis V, Schechner R, Mallis M, Rosegreen S, Glicklich D, Moore N y cols.: No-Load Sirolimus With Tacrolimus and Steroids Is Safe and Effective in Renal Transplantation. Transplantation Proceedings 37 (2): 906-908, 2005.
240. Woodle ES, Vincenti F, Lorber MI, Gritsch HA, Hricik D, Washburn K y cols.: A multicenter pilot study of early4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 5 (1): 157-166, 2005.
241. Kaufman DB, Leventhal JR, Koffron AJ, Gallon LG, Parker MA, Fryer JP y cols.: A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation: comparison of two maintenance immunosuppression protocols: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 73 (2): 169-177, 2002.
242. Rogers CC, Hanaway M, Alloway RR, Alexander JW, Boardman RE, Trofe J y cols.: Corticosteroid Avoidance Ameliorates Lymphocele Formation and Wound Healing Complications Associated With Sirolimus Therapy. Transplantation Proceedings 37 (2): 795-797, 2005.
243. Flechner SM, Feng J, Mastroianni B, Savas K, Arnovitz J, Moneim H y cols.: The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 79 (8): 926-934, 2005.
244. Ponticelli C, Passerini P: Gastrointestinal complications in renal transplant recipients. Transpl Int 18 (6): 643-650, 2005.
245. Romero DF, Buchinsky FJ, Rucinski B, Cvetkovic M, Bryer HP, Liang XG y cols.: Rapamycin: a bone sparing immunosuppressant? J Bone Miner Res 10 (5): 760-768, 1995.
246. Joffe I, Katz I, Sehgal S, Bex F, Kharode Y, Tamasi J y cols.: Lack of change of cancellous bone volume with short-term use of the new immunosuppressant rapamycin in rats. Calcif Tissue Int 53 (1): 45-52, 1993.
247. Goodman GR, Dissanayake IR, Sodam BR, Gorodetsky E, Lu J, Ma YF y cols.: Immunosuppressant use without bone loss-implications for bone loss after transplantation. J Bone Miner Res 16 (1): 72-78, 2001.
248. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T y cols.: Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 280 (1): 334-339, 2001.
249. Sánchez CP, He YZ: Rapamycin: Effects on the growth plate in young rats. En: Journal of the American Society of Nephrology; 2002; 35th Annual Meeting, american society of Nephrology, October 30-November 4, 2002; 2002. p. 183A.
250. Campistol JM, Holt DW, Epstein S, Gioud-Paquet M, Rutault K, Burke JT y cols.: Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int 18 (9): 1028-1035, 2005.
251. Campistol JM, Font B, Vila A, Lomeá F, Oppenheimer F. REFLEX SYMPATHETIC DYSTROPHY LIKE-SYNDROME (RSDLS) ASSOCIATED WITH SIROLIMUS THERAPY. En: Transplantation p. 289, 2000.
252. Bhandari S, Eris J: Premature osteonecrosis and sirolimus treatment in renal transplantation. BMJ 323 (7314): 665, 2001.
253. Boardman RE, Trofe J, Alloway RR, Rogers C, Roy-Chaudhury P, Cordi M y cols.: BONE PAIN IN RENAL TRANSPLANTATION: DOES SIROLIMUS PLAY A ROLE? En: Am J Transplant; 2004; American Transplant Congress, May 14 -19, 2004, Boston, MA; 2004.
254. Swinford RD, Braun MC, Sorof JM, Kahan BD, Portman RJ. Sirolimus does not adversely affect growth in children post kidney transplant. In: Journal of the American Society of Nephrology; 2002; 35th Annual Meeting, american society of Nephrology, October 30-November 4, 2002; p. 570A.
255. Cunningham J: Posttransplantation bone disease. Transplantation (6): 629-634, 2005.
256. Torres A, Lorenzo V, Salido E: Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 13 (2): 551-558, 2002.
257. Torregrosa JV, Diekmann F, Campistol JM, Saval N, Fuster D, Oppenheimer F: WEEKLY RISEDRONATE IN KIDNEY TRANSPLANT PATIENTS WITH OSTEOPENIA-OSTEOPOROSIS. En; 2005; XLII ERA-EDTA Congress, June 4-7, 2005, Istambul (Turkey); 2005.
258. Morelon E, Stern M, Kreis H: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 343 (3): 225-226, 2000.
259. Morelon E, Stern M, Israel-Biet D, Correas JM, Danel C, Mamzer-Bruneel MF y cols.: Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72 (5): 787-790, 2001.
260. Champion L, Morelon E, Stern M, Mamzer-Bruneel MF, Rerolle JP, Peraldi MN y cols.: SIROLIMUS-RELATED INTERSTITIAL PNEUMONITIS: REPORT OF 21 CASES IN RENAL TRANSPLANT RECIPIENTS. En: Am J Transplant; 2004; American Transplant Congress, May 14-19, 2004, Boston, MA; 2004.
261. Avitzur Y, Jiménez-Rivera C, Fecteau A, Jones N, Ngan BY, Ng VL: Interstitial granulomatous pneumonitis associated with sirolimus in a child after liver transplantation. J Pediatr Gastroenterol Nutr 37 (1): 91-94, 2003.
262. Singer SJ, Tiernan R, Sullivan EJ: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 343 (24): 1815-1816, 2000
263. Digon BJ, III, Rother KI, Hirshberg B, Harlan DM: Sirolimus-Induced Interstitial Pneumonitis in an Islet Transplant Recipient. Diabetes Care 26 (11): 3191, 2003.
264. Nayak SK, Jeloka TK, Sreepada SV: Sirolimus-induced pneumonitis, sinusitis and macular oedema. Nephrol Dial Transplant (11): 2931, 2004.
265. Manito N, Kaplinsky EJ, Bernat R, Roca J, Castells E, Serrano T y cols.: Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. The Journal of Heart and Lung Transplantation 23 (6): 780-782, 2004.
266. Shefet D, Ben-Dor I, Lustig S: Sirolimus-induced interstitial pneumonitis after renal transplantation. Transplantation 78 (6): 950, 2004.
267. McWilliams TJ, Levvey BJ, Russell PA, Milne DG, Snell GI: Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant 22 (2): 210-213, 2003.
268. Haydar AA, Denton M, West A, Rees J, Goldsmith DJ: Sirolimus-induced pneumonitis: three cases and a review of the literature. Am J Transplant 4 (1): 137-139, 2004.
269. Lennon A, Finan K, FitzGerald MX, McCormick PA: Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation. Transplantation 72 (6): 1166-1167, 2001.
270. Kaplan MJ, Ellis CN, Bata CZ, Kaplan RS, Endres JL, Fox DA: Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: Association of capillary leak syndrome with apoptosis of lesional lymphocytes. Archives of Dermatology 135 (5): 553-557, 1999.
271. Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA y cols.: Sirolimus-Associated Pulmonary Toxicity. Transplantation 77 (8): 1215-1220, 2004.
272. Hamour IM, Mittal TK, Bell AD, Banner NR: Reversible Sirolimus-Associated Pneumonitis After Heart Transplantation. The Journal of Heart and Lung Transplantation 25 (2): 241-244, 2006.
273. Mingos MA, Kane GC: Sirolimus-induced interstitial pneumonitis in a renal transplant patient. Respir Care 50 (12): 1659-1661, 2005.
274. Amigues L, Klouche K, Massanet P, Gaillard N, Garrigue V, Beraud JJ y cols.: Sirolimus-associated acute respiratory distress syndrome in a renal transplant recipient. Transplant Proc 37 (6): 2830-2831, 2005.
275. Garrean S, Massad MG, Tshibaka M, Hanhan Z, Caines AE, Benedetti E: Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients. Clin Transplant 19 (5): 698-703, 2005.
276. Chhajed PN, Dickenmann M, Bubendorf L, Mayr M, Steiger J, Tamm M: Patterns of Pulmonary Complications Associated with Sirolimus. Respiration 73 (3): 367-374, 2006.
277. Delgado JF, Torres J, Ruiz-Cano MJ, Sánchez V, Escribano P, Matia R y cols.: Sirolimus associated interstitial pneumonitis in heart transplant recipients. The Journal of Heart and Lung Transplantation 25 (2, Supl. 1): 122, 2006.
278. Mahalati K, Murphy DM, West ML: Bronchiolitis obliterans and organizing pneumonia in renal transplant recipients. Transplantation 69 (7): 1531-1532, 2000.
279. Lindenfeld JA, Simon SF, Zamora MR, Cool CD, Wolfel EE, Lowes BD y cols.: BOOP is Common in Cardiac Transplant Recipients Switched from a Calcineurin Inhibitor to Sirolimus. Am J Transplant 5 (6): 1392-1396, 2005.
280. Henry MT, Newstead CG: Sirolimus: Another cause of druginduced interstitial pneumonitis. Transplantation 72 (5): 773-774, 2001.
281. Serkova N, Christians U, Flogel U, Pfeuffer J, Leibfritz D. Assessment of the mechanism of astrocyte swelling induced by the macrolide immunosuppressant sirolimus using multinuclear nuclear magnetic resonance spectroscopy. Chem Res Toxicol 10 (12): 1359-1363, 1997.
282. Maramattom BV, Wijdicks EF: Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients. Neurology (10): 1958-1959, 2004.
283. Neff GW, Montalbano M, Tzakis AG: Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 35 (3 Supl.): S209-S216, 2003.
284. Sindhi R, Seward J, Mazariegos G, Soltys K, Seward L, Smith A y cols.: Replacing calcineurin inhibitors with mTOR inhibitors in children. Pediatric Transplantation 9 (3): 391-397, 2005.
285. Hodges CB, Maxwell H, Beattie TJ, Murphy AV, Jindal RM: Use of rapamycin in a transplant patient who developed cyclosporin neurotoxicity. Pediatr Nephrol 16 (10): 777-778, 2001.
286. Toth CC, Burak K, Becker W: Recurrence of Migraine With Aura Due to Tacrolimus Therapy in a Liver Transplant Recipient Successfully Treated With Sirolimus Substitution. Headache (3): 245-246, 2005.
287. th Annual Meeting, american society of Nephrology, October 30-November 4, p. 773A.
288. Forgacs B, Merhav HJ, Lappin J, Mieles L: Successful Conversion to Rapamycin for Calcineurin Inhibitor-Related Neurotoxicity Following Liver Transplantation. Transplantation Proceedings 37 (4): 1912-1914, 2005.
289. Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP y cols.: Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 6 (6): 734-740, 2000.
290. Sindhi R, Webber S, Venkataramanan R, McGhee W, Phillips S, Smith A y cols.: Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. Transplantation 72 (5): 851-855, 2001.
291. Fridell JA, Jain AK, Patel K, Virji M, Rao KN, Fung JJ y cols.: Phenytoin decreases the blood concentrations of sirolimus in a liver transplant recipient: a case report. Ther Drug Monit (1): 117-119, 2003.
292. Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M, Spetz JF y cols.: Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 24 (21): 9508-9516, 2004.
293. Jankowska I, Oldakowska-Jedynak U, Jabiry-Zieniewicz Z, Cyganek A, Pawlowska J, Teisseyre M y cols.: Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient. Transplantation Proceedings 36 (10): 3232-3233, 2004.
294. Cowan SW, Lavelanet A, Coscia LA, Moritz MJ, Armenti VT. PREGNANCIES FATHERED BY MALE KIDNEY TRANSPLANT RECIPIENTS ON NEWER IMMUNOSUPPRESSIVE MEDICATIONS. En: Am J Transplant; 2004; American Transplant Congress, May 14-19, 2004, Boston, MA; 2004.
295. McKay DB, Josephson MA: Reproduction and Transplantation: Report on the AST Consensus Conference on Reproductive Issues and Transplantation.
296. Geissler EK, Schlitt HJ: The relation between immunosuppressive agents and malignancy. Curr Opin Organ Transplant (4): 394-399, 2004.
297. Mathew T, Kreis H, Friend P: Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transpl 18 (4): 446-449, 2004.
298. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchinson B, Morales JM y cols.: Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 17 (2): 581-589, 2006.
299. Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D y cols.: Low Incidence of Malignancy among Sirolimus/ Cyclosporine-Treated Renal Transplant Recipients. Transplantation 80 (6): 749-758, 2005.
300. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD: Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies. Transplantation 80 (7): 883-889, 2005.
301. Zmonarski SC, Boratynska M, Rabczynski J, Kazimierczak K, Klinger M: Regression of Kaposi's Sarcoma in Renal Graft Recipients After Conversion to Sirolimus Treatment. Transplant Proc 37 (2): 964-966, 2005.
302. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G y cols.: Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients. N Engl J Med 352 (13): 1317-1323, 2005.
303. Campistol JM, Gutiérrez-Dalmau A, Torregrosa JV: Conversion to sirolimus: a successful treatment for post-transplantation Kaposi's sarcoma. Transplantation 77 (5): 760-762, 2004.
304. Dantal J, Jumbou O, Cantarovich D, Hourmant M, Giral M, Blancho G y cols.: Reduction of Skin Cancer Recurrence after Conversion to Sirolimus in Kidney Transplant Patients. En: J Am Soc Nephrol; 2004; Renal Week 2004, October 27-November 1, 2004, America's Center, St. Louis, Missouri; 2004.
305. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J: Complete Remission of Post-transplant Lung Metastases from Hepatocellular Carcinoma under Therapy with Sirolimus and Mycophenolate Mofetil. Transplantation 79 (7): 855-857, 2005.
306. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM y cols.: Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 10 (10): 1301, 2004.
307. Al-Akash SI, Al Makadma AS, Al Omari MG: Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant 9 (2): 249-253, 2005.
308. Komrokji RS, Oliva JL, Zand M, Felgar R, Abboud CN: Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol 79 (3): 211-215, 2005.
309. Garcia VD, Filho JL, Neumann J, Fogliatto L, Geiger AM, Garcia CD y cols.: Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 16 (3): 202-206, 2003.
310. Jiménez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL: Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma*. Pediatr Transplant 8 (3): 243-248, 2004.
311. Kumar MSA, Heifets M, Moritz MJ, Parikh MH, Saeed MI, Fyfe B y cols.: SIROLIMUS (SLR) THERAPY IN KIDNEY RECIPIENTS WITH PAST CANCER PREVENTS RECURRENCE OF CANCER AFTER TRANSPLANTATION: 3 YEAR POST TRANSPLANT EXPERIENCE. En: Am J Transplant; 2005; American Transplant Congress, Seattle; 2005.